10/27/2026
The stage is set for some of our most important gatherings of the year.
Over the next two days, FARE’s inaugural Alpha-Gal Syndrome Convening & fifth annual Clinical Development Day will bring together experts spanning diverse disciplines to accelerate research and improve care for individuals living with food allergy.
Although these events are invitation-only, you can follow along here as we share highlights and what these discussions could mean for the future of food allergy.
Our first event, held Wednesday, focuses on alpha-gal syndrome (AGS), a potentially life-threatening allergy associated with tick bites that causes reactions to mammalian-derived ingredients such as beef, pork, and lamb, among others. With AGS cases rising across the U.S., we’re developing a strategic, coordinated approach to AGS research, prevention, diagnosis, and education.
Because food allergy affects everyone differently, FARE recognizes that treatment approaches should reflect those differences. Our Clinical Development Day brings together researchers, clinicians, regulators, and industry leaders to explore how advances in science can lead to more personalized treatment approaches, better clinical trials, and improved outcomes for people living with food allergy.
Many of our guests have food allergy, including alpha-gal. So alongside the skillful team at the Dupont Circle Hotel, we’ve extensively refined the menus for this event in the hopes our guests will feel the same attention and care they’ve dedicated to our community.
With weeks of preparation now behind us, we are filled with hope—hope that together, we will overcome obstacles and make connections which move the field forward for those counting on a cure.